Evidence map›Paper›PMID 34564443›Full record

ArticleMetabolites2021

Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer.

Nicholas D Nguyen, Meifang Yu, Vinit Y Reddy, Ariana C Acevedo-Diaz, Enzo C Mesarick, Joseph Abi Jaoude, Min Yuan, John M Asara, Cullen M Taniguchi

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Nicholas D NguyenDepartment of Experimental Radiation Oncology, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3481-0672
Meifang YuDepartment of Experimental Radiation Oncology, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA.
Vinit Y ReddyDepartment of Experimental Radiation Oncology, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA.
Ariana C Acevedo-DiazDepartment of Experimental Radiation Oncology, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-5872-232X
Enzo C MesarickDepartment of Experimental Radiation Oncology, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA.
Joseph Abi JaoudeDepartment of Experimental Radiation Oncology, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA.
Min YuanDivision of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
John M AsaraDivision of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.ORCID 0000-0001-7450-2589
Cullen M TaniguchiDepartment of Experimental Radiation Oncology, The University of Texas at MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-8052-3316
The University of Texas MD Anderson Cancer Center · USBeth Israel Deaconess Medical Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Cancer Prevention and Research Institute of Texas RR140012NCI NIH HHS CCSG P30CA016672NIH HHS R01CA227517-01A1V Foundation for Cancer Research V2015-22
6 · The paper itself

Abstract

Mitochondria are dynamic organelles that constantly alter their shape through the recruitment of specialized proteins, like mitofusin-2 (Mfn2) and dynamin-related protein 1 (Drp1). Mfn2 induces the fusion of nearby mitochondria, while Drp1 mediates mitochondrial fission. We previously found that the genetic or pharmacological activation of mitochondrial fusion was tumor suppressive against pancreatic ductal adenocarcinoma (PDAC) in several model systems. The mechanisms of how these different inducers of mitochondrial fusion reduce pancreatic cancer growth are still unknown. Here, we characterized and compared the metabolic reprogramming of these three independent methods of inducing mitochondrial fusion in KPC cells: overexpression of Mfn2, genetic editing of Drp1, or treatment with leflunomide. We identified significantly altered metabolites via robust, orthogonal statistical analyses and found that mitochondrial fusion consistently produces alterations in the metabolism of amino acids. Our unbiased methodology revealed that metabolic perturbations were similar across all these methods of inducing mitochondrial fusion, proposing a common pathway for metabolic targeting with other drugs.

Indexed as

fissionfusionleflunomidemetabolomic reprogrammingmetabolomicsmitochondrial morphologymitofusin-2pancreatic cancer

Identifiers

PMID34564443
PMCPMC8470144
OpenAlexW3201061616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.